Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13616492 | 0.81 | ALDH1A1 (0.68) | MAPTLMNAALDH1A1MAPK1KDM4E | |
| SCHEMBL4315406 | 0.80 | MAPT (0.72) | MAPTLMNAALDH1A1MAPK1KDM4E | |
| SCHEMBL13616566 | 0.77 | SMN1; SMN2 (0.52) | MAPTLMNAALDH1A1MAPK1KDM4E | |
| SCHEMBL13749573 | 0.68 | LMNA (0.51) | MAPTLMNAALDH1A1MAPK1KDM4E | |
| SCHEMBL13616470 | 0.66 | MAPT (0.39) | MAPTLMNAALDH1A1MAPK1KDM4E | |
| SCHEMBL282040 | 0.65 | ALDH1A1 (0.53) | MAPTLMNAALDH1A1MAPK1KDM4E | |
| SCHEMBL12715362 | 0.65 | CYP3A4 (0.56) | MAPTLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL13616563 | 0.65 | MAPK1 (0.39) | MAPTLMNAALDH1A1MAPK1KDM4E | |
| SCHEMBL11628473 | 0.65 | LMNA (0.73) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL13616467 | 0.65 | SMN1; SMN2 (0.47) | MAPTLMNAMAPK1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275594-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275594-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | RIF1, ABCC1, HDAC6 | MAPT 3175/4885LMNA 2521/4885ALDH1A1 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.